Figure 2. Lnc-EPIC1 siRNA inhibits colon cancer cell growth, proliferation, migration and invasion. The primary human colon cancer cells, pri-Can-1/-2/-3, were transfected with scramble control siRNA (“scr”, 500 nM) or the applied Lnc-EPIC1 siRNA (si-Lnc-EPIC1-s1/si-Lnc-EPIC1-s2, 500 nM), cells were further cultured for 48h, and expression of Lnc-EPIC1 and linear EPIC1 was tested by qPCR assays (A, B, H); Cells were further cultured for applied time periods, cell viability was examined by CCK-8 assays (C, I); Cell growth and proliferation were examined by cell counting assay (D) and nuclear EdU staining (E, J). Cell migration and invasion were tested by “Transwell” (F) and “Matrigel Transwell” (G) assays, respectively. For EdU studies, ten random views of each treatment were included to calculate the average EdU ratio (% vs. DAPI, same for all Figures). For “Transwell”/“Martial Transwell” assays, in each condition ten random views were included to calculate the average number of migrated/invaded cells (same for all Figures). The exact same number of viable colon cancer cells with different genetic modifications were initially seeded into each well or each dish (at 0h, same for all Figures). “pare” stands for the parental control cells (same for all Figures). Data presented as mean ± standard deviation (SD). * p< 0.05 vs. “scr” cells. Experiments in this figure were repeated five times. Bar=100 μm (E–G).